प्राथमिक स्रोत रिकॉर्ड
महत्वपूर्णआवेदन जमा
Jazz Pharmaceuticals: 1L GEA में zanidatamab की sBLA प्रस्तुति 2026 की पहली छमाही (1H26) में योजनाबद्ध
Jazz Pharmaceuticals plans to submit a supplemental Biologics License Application (sBLA) for zanidatamab in first-line (1L) GEA in the first half of 2026. This submission is based on positive Phase 3 HERIZON-GEA-01 study data, which suggests zanidatamab plus chemotherapy could become the new standard of care for HER2+ GEA.
मुख्य तथ्य
- फाइल किया गया
- 12 जन॰ 2026, 02:01 pm
- घटना
- आवेदन जमा
- दिशा
- सकारात्मक
- स्रोत
- SEC 8-K
- विश्वसनीयता
- स्रोत सहित
स्रोत का अंश
EX-99.1 2 d61589dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 January 2026 44th Annual J.P. Morgan Healthcare Conference Redefining Possibilities in Rare Disease Renee Gala, President & CEO Transforming Lives. Redefining Possibilities. Caution Concerning Forward-Looking Statements This presentation contains forward-looking statements and financial targets, including, but not limited to, statements related to: the Company’s growth prospects and future financial and operating results, including the ability of the Company’s portfolio to drive long-term shareholder value; expectations with respect to indication expansion opportunities; 2025 total revenue guidance and 2025 revenue for each of Xywav, Epidiolex and Modeyso and the Company’s expectations related thereto; the Company’s ability to dri